Role of cytoreduction in stage III and IV uterine papillary serous carcinoma

M. Bijoy Thomas, Andrea Mariani, William Arthur Cliby, Gary Keeney, Karl C. Podratz, Sean Christopher Dowdy

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Objective: Uterine papillary serous carcinoma (UPSC) frequently presents in advanced stages. The aim of this study was to assess the role of cytoreduction in stage IIIC-IV UPSC. Methods: Retrospective review was conducted of UPSC from 1982 through 2005. Surgical treatment consisted of hysterectomy, removal of adnexae, and pelvic and paraaortic lymphadenectomy, with or without tumor cytoreduction. Median follow-up was 21 months. Results: Of the 125 UPSC patients, analysis of stage IIIC-IV patients (n = 70; stage IIIC 12, stage IV 58) was performed. Optimal cytoreduction was achieved in 42 of 70 (60%) patients, and optimal cytoreduction with no visible residual disease in 26 of 70 (37%) patients. Patients with no visible residual disease after cytoreduction had a better median survival (51 months) compared to optimally cytoreduced albeit with residual disease (14 months), and suboptimally cytoreduced patients (12 months) (p-value = 0.002). Of the 45 patients who received CT, the median survival of patients with no residual disease vs. patients with residual disease was 52 months vs. 16 months (p < 0.001) respectively. No reduction in survival was noted when radical procedures were necessary to completely remove all residual disease. Regression analysis identified absence of visible residual disease (hazard ratio (HR) = 0.30, p < 0.001) and CT (HR = 0.56, p = 0.07) as independent predictors of OS. Discussion: Cytoreduction to no gross residual disease and the use of CT are associated with a significant survival benefit for patients with stage IIIC-IV UPSC. This effect persisted even in patients who underwent radical resections.

Original languageEnglish (US)
Pages (from-to)190-193
Number of pages4
JournalGynecologic Oncology
Volume107
Issue number2
DOIs
StatePublished - Nov 2007

Fingerprint

Papillary Carcinoma
Survival
Lymph Node Excision
Hysterectomy
Regression Analysis

Keywords

  • Advanced endometrial cancer
  • Cytoreduction
  • Uterine papillary serous cancer

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Role of cytoreduction in stage III and IV uterine papillary serous carcinoma. / Thomas, M. Bijoy; Mariani, Andrea; Cliby, William Arthur; Keeney, Gary; Podratz, Karl C.; Dowdy, Sean Christopher.

In: Gynecologic Oncology, Vol. 107, No. 2, 11.2007, p. 190-193.

Research output: Contribution to journalArticle

@article{88d19e1680bc4ce6a6065f294c013609,
title = "Role of cytoreduction in stage III and IV uterine papillary serous carcinoma",
abstract = "Objective: Uterine papillary serous carcinoma (UPSC) frequently presents in advanced stages. The aim of this study was to assess the role of cytoreduction in stage IIIC-IV UPSC. Methods: Retrospective review was conducted of UPSC from 1982 through 2005. Surgical treatment consisted of hysterectomy, removal of adnexae, and pelvic and paraaortic lymphadenectomy, with or without tumor cytoreduction. Median follow-up was 21 months. Results: Of the 125 UPSC patients, analysis of stage IIIC-IV patients (n = 70; stage IIIC 12, stage IV 58) was performed. Optimal cytoreduction was achieved in 42 of 70 (60{\%}) patients, and optimal cytoreduction with no visible residual disease in 26 of 70 (37{\%}) patients. Patients with no visible residual disease after cytoreduction had a better median survival (51 months) compared to optimally cytoreduced albeit with residual disease (14 months), and suboptimally cytoreduced patients (12 months) (p-value = 0.002). Of the 45 patients who received CT, the median survival of patients with no residual disease vs. patients with residual disease was 52 months vs. 16 months (p < 0.001) respectively. No reduction in survival was noted when radical procedures were necessary to completely remove all residual disease. Regression analysis identified absence of visible residual disease (hazard ratio (HR) = 0.30, p < 0.001) and CT (HR = 0.56, p = 0.07) as independent predictors of OS. Discussion: Cytoreduction to no gross residual disease and the use of CT are associated with a significant survival benefit for patients with stage IIIC-IV UPSC. This effect persisted even in patients who underwent radical resections.",
keywords = "Advanced endometrial cancer, Cytoreduction, Uterine papillary serous cancer",
author = "Thomas, {M. Bijoy} and Andrea Mariani and Cliby, {William Arthur} and Gary Keeney and Podratz, {Karl C.} and Dowdy, {Sean Christopher}",
year = "2007",
month = "11",
doi = "10.1016/j.ygyno.2007.05.039",
language = "English (US)",
volume = "107",
pages = "190--193",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Role of cytoreduction in stage III and IV uterine papillary serous carcinoma

AU - Thomas, M. Bijoy

AU - Mariani, Andrea

AU - Cliby, William Arthur

AU - Keeney, Gary

AU - Podratz, Karl C.

AU - Dowdy, Sean Christopher

PY - 2007/11

Y1 - 2007/11

N2 - Objective: Uterine papillary serous carcinoma (UPSC) frequently presents in advanced stages. The aim of this study was to assess the role of cytoreduction in stage IIIC-IV UPSC. Methods: Retrospective review was conducted of UPSC from 1982 through 2005. Surgical treatment consisted of hysterectomy, removal of adnexae, and pelvic and paraaortic lymphadenectomy, with or without tumor cytoreduction. Median follow-up was 21 months. Results: Of the 125 UPSC patients, analysis of stage IIIC-IV patients (n = 70; stage IIIC 12, stage IV 58) was performed. Optimal cytoreduction was achieved in 42 of 70 (60%) patients, and optimal cytoreduction with no visible residual disease in 26 of 70 (37%) patients. Patients with no visible residual disease after cytoreduction had a better median survival (51 months) compared to optimally cytoreduced albeit with residual disease (14 months), and suboptimally cytoreduced patients (12 months) (p-value = 0.002). Of the 45 patients who received CT, the median survival of patients with no residual disease vs. patients with residual disease was 52 months vs. 16 months (p < 0.001) respectively. No reduction in survival was noted when radical procedures were necessary to completely remove all residual disease. Regression analysis identified absence of visible residual disease (hazard ratio (HR) = 0.30, p < 0.001) and CT (HR = 0.56, p = 0.07) as independent predictors of OS. Discussion: Cytoreduction to no gross residual disease and the use of CT are associated with a significant survival benefit for patients with stage IIIC-IV UPSC. This effect persisted even in patients who underwent radical resections.

AB - Objective: Uterine papillary serous carcinoma (UPSC) frequently presents in advanced stages. The aim of this study was to assess the role of cytoreduction in stage IIIC-IV UPSC. Methods: Retrospective review was conducted of UPSC from 1982 through 2005. Surgical treatment consisted of hysterectomy, removal of adnexae, and pelvic and paraaortic lymphadenectomy, with or without tumor cytoreduction. Median follow-up was 21 months. Results: Of the 125 UPSC patients, analysis of stage IIIC-IV patients (n = 70; stage IIIC 12, stage IV 58) was performed. Optimal cytoreduction was achieved in 42 of 70 (60%) patients, and optimal cytoreduction with no visible residual disease in 26 of 70 (37%) patients. Patients with no visible residual disease after cytoreduction had a better median survival (51 months) compared to optimally cytoreduced albeit with residual disease (14 months), and suboptimally cytoreduced patients (12 months) (p-value = 0.002). Of the 45 patients who received CT, the median survival of patients with no residual disease vs. patients with residual disease was 52 months vs. 16 months (p < 0.001) respectively. No reduction in survival was noted when radical procedures were necessary to completely remove all residual disease. Regression analysis identified absence of visible residual disease (hazard ratio (HR) = 0.30, p < 0.001) and CT (HR = 0.56, p = 0.07) as independent predictors of OS. Discussion: Cytoreduction to no gross residual disease and the use of CT are associated with a significant survival benefit for patients with stage IIIC-IV UPSC. This effect persisted even in patients who underwent radical resections.

KW - Advanced endometrial cancer

KW - Cytoreduction

KW - Uterine papillary serous cancer

UR - http://www.scopus.com/inward/record.url?scp=35348921403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348921403&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2007.05.039

DO - 10.1016/j.ygyno.2007.05.039

M3 - Article

VL - 107

SP - 190

EP - 193

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -